Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Futu Holdings Ltd (FUTU) Price & Performance

Cytokinetics IncTrade
Futu Holdings LtdTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Futu Holdings Ltd — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Futu Holdings Ltd trades at $105.19 (market cap $14.74B). The key difference: Futu Holdings Ltd is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.47% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKFUTU
Market Cap
$10.63B$14.74B
Sector
TechnologyFinancials
52-Week High
$87.26$199.04
52-Week Low
$34.31$89.76
Enterprise Value
$10.74B$14.59B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.

The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.

Futu Holdings Ltd

FUTU trades at $105.41, down 3.03% today, amid a securities class action filing alleging regulatory compliance failures. The stock shows strong fundamentals with a P/E of 11.63 and net income margin of 41.83%, supported by robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Technical indicators are bullish on moving averages, with key support at $103 and resistance at $110.

The outlook is mixed: strong profitability and analyst consensus (58% buy ratings) support upside, but legal risks and recent earnings misses pose significant headwinds. Investors should weigh solid financials against litigation overhang and market sentiment pressures.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Futu Holdings Ltd

Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.

Read more on FUTU